Overdiagnosis and Breast Cancer Screening Decisions
Launched by YALE UNIVERSITY · Jul 7, 2025
Trial Information
Current as of July 25, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This study is looking at how learning about “overdiagnosis” might affect older women’s decisions about breast cancer screening using mammograms. Overdiagnosis means finding a cancer that would not have caused any problems during a person’s lifetime, which can sometimes lead to unnecessary treatments. The researchers want to see if giving women more information about this changes their thoughts or plans about continuing regular breast cancer screening.
Women who are 70 years or older, who have never had breast cancer or a related condition, and who can take an online survey in English may be able to participate. During the study, participants will answer questions about what they know and believe about breast cancer screening and whether they plan to keep getting screened. Then, they will watch one of several short videos—some explaining overdiagnosis and one that does not mention it. After watching, they will answer similar questions again to see if their views have changed. This study helps doctors understand how best to share information so women can make informed choices about their health.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 70 and older
- • Able to participate in an English-language web-based survey
- Exclusion Criteria:
- • Prior history of breast cancer or ductal carcinoma in situ
About Yale University
Yale University, a prestigious Ivy League institution located in New Haven, Connecticut, is renowned for its commitment to advancing medical research and clinical innovation. With a rich history of academic excellence and a robust infrastructure for scientific inquiry, Yale serves as a leading sponsor for clinical trials aimed at improving patient care and developing new therapeutic approaches. The university's multidisciplinary teams of researchers and clinicians collaborate to conduct rigorous and ethical studies, leveraging cutting-edge technologies and methodologies to address critical health challenges. Through its dedication to fostering an environment of inquiry and discovery, Yale University plays a pivotal role in translating research findings into clinical practice, ultimately enhancing health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Haven, Connecticut, United States
Patients applied
Trial Officials
Ilana Richman, MD
Principal Investigator
Yale University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported